ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,005Medicare Part D Prescriptions Filled, Including Refills

Rank: 411 out of 2652

$607K Total Retail Price of All Prescriptions

Rank: 371 out of 2652

425 Patients Receiving at Least One Drug in Part D
74% Patients 65 Years and Older
64% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in Illinois
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

20% of this provider’s 425 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in Illinois
AMLODIPINE BESYLATE 391 269 78 1 3
LISINOPRIL 373 264 75 2 4
HYDROCODONE-ACETAMINOPHEN 303 121 71 S3 3 8
HYDROCHLOROTHIAZIDE 278 204 57 4 13
FUROSEMIDE 273 201 69 5 5
SIMVASTATIN 270 205 71 6 1
METOPROLOL SUCCINATE 266 167 58 7 12
ATORVASTATIN CALCIUM 234 129 73 8 6
LEVOTHYROXINE SODIUM 229 147 38 9 2
OMEPRAZOLE 202 124 50 10 7
WARFARIN SODIUM 197 192* 30 11 11
METFORMIN HCL 193 130 43 12 9
METOPROLOL TARTRATE 183 156 44 13 10
NAPROXEN 135 81 45 14 97
GABAPENTIN 132 86 32 15 18
ATENOLOL 119 83 23 16 17
CLONIDINE HCL 118 73 26 17 64
PRAVASTATIN SODIUM 116 101 31 18 19
POTASSIUM CHLORIDE 115 91 29 19 16
GLIMEPIRIDE 114 109* 26 20 41
PANTOPRAZOLE SODIUM 111 97 26 21 20
CARVEDILOL 106 82 19 22 21
DONEPEZIL HCL 103 98* 23 23 24
CLOPIDOGREL 99 58 27 24 15
QUETIAPINE FUMARATE 89 <11 <11 A 25 59
METFORMIN HCL ER 79 61 17 26 67
PREDNISONE 78 62 26 27 43
PROAIR HFA 77 44 34 28 39
CYMBALTA 77 20 11 28 60
CIPROFLOXACIN HCL 76 61 59 30 82
TRAMADOL HCL 76 34 34 30 22
IBUPROFEN 74 42 29 32 70
ZOLPIDEM TARTRATE 71 32 27 33 32
DIOVAN 69 52 12 34 33
FLUTICASONE PROPIONATE 69 34 29 34 38
LOSARTAN POTASSIUM 69 56 24 34 14
GLIPIZIDE ER 68 <11 <11 37 84
HYDRALAZINE HCL 67 56 21 38 54
NIFEDIPINE ER 67 62* 15 38 69
GLIPIZIDE 67 52 11 38 44
AZITHROMYCIN 64 40 50 41 51
ALPRAZOLAM 63 58* 26 B 42 26
CRESTOR 62 15 14 43 29
LEVOFLOXACIN 62 45 43 43 74
LANTUS SOLOSTAR 62 41 18 43 75
LOSARTAN-HYDROCHLOROTHIAZIDE 60 44 12 46 55
KLOR-CON M20 60 28 13 46 57
ACETAMINOPHEN-CODEINE 58 53* 15 S3 48 93
KLOR-CON 10 57 31 21 49 91
TRIAMCINOLONE ACETONIDE 55 44 32 50 98
SPIRIVA 54 49* 11 51 63
ENALAPRIL MALEATE 53 35 14 52 34
JANUVIA 50 22 11 53 52
TRIAMTERENE-HCTZ 50 45* 13 53 47
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.